Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221138045> ?p ?o ?g. }
- W4221138045 abstract "Abstract Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors due to toxicity, relying only on palliative chemotherapy and the third-generation tyrosine kinase inhibitor (TKI) osimertinib. This new drug extends lifespan by 9-months vs . second-generation TKIs, but unfortunately, cancers relapse due to resistance mechanisms and the lack of antitumor immune responses. Here we explored the combination of osimertinib with anti-HER3 monoclonal antibodies and observed that the immune system contributed to eliminate tumor cells in mice and co-culture experiments using bone marrow-derived macrophages and human PBMCs. Osimertinib led to apoptosis of tumors but simultaneously, it triggered inositol-requiring-enzyme (IRE1α)-dependent HER3 upregulation, increased macrophage infiltration, and activated cGAS in cancer cells to produce cGAMP (detected by a lentivirally transduced STING activity biosensor), transactivating STING in macrophages. We sought to target osimertinib-induced HER3 upregulation with monoclonal antibodies, which engaged Fc receptor-dependent tumor elimination by macrophages, and STING agonists enhanced macrophage-mediated tumor elimination further. Thus, by engaging a tumor non-autonomous mechanism involving cGAS-STING and innate immunity, the combination of osimertinib and anti-HER3 antibodies could improve the limited therapeutic and stratification options for advanced stage lung cancer patients with mutant EGFR." @default.
- W4221138045 created "2022-04-03" @default.
- W4221138045 creator A5000082261 @default.
- W4221138045 creator A5000945719 @default.
- W4221138045 creator A5009276756 @default.
- W4221138045 creator A5010245558 @default.
- W4221138045 creator A5011112591 @default.
- W4221138045 creator A5011564773 @default.
- W4221138045 creator A5012486076 @default.
- W4221138045 creator A5012567466 @default.
- W4221138045 creator A5018810463 @default.
- W4221138045 creator A5026888592 @default.
- W4221138045 creator A5033067260 @default.
- W4221138045 creator A5035783276 @default.
- W4221138045 creator A5038055187 @default.
- W4221138045 creator A5038869356 @default.
- W4221138045 creator A5043518753 @default.
- W4221138045 creator A5043891387 @default.
- W4221138045 creator A5044515513 @default.
- W4221138045 creator A5046959069 @default.
- W4221138045 creator A5046997933 @default.
- W4221138045 creator A5047563830 @default.
- W4221138045 creator A5049250271 @default.
- W4221138045 creator A5052659347 @default.
- W4221138045 creator A5052752522 @default.
- W4221138045 creator A5054414352 @default.
- W4221138045 creator A5055396042 @default.
- W4221138045 creator A5056125672 @default.
- W4221138045 creator A5057713664 @default.
- W4221138045 creator A5057992394 @default.
- W4221138045 creator A5059744684 @default.
- W4221138045 creator A5061075583 @default.
- W4221138045 creator A5061863831 @default.
- W4221138045 creator A5062167352 @default.
- W4221138045 creator A5065639296 @default.
- W4221138045 creator A5071383065 @default.
- W4221138045 creator A5075702502 @default.
- W4221138045 creator A5077363582 @default.
- W4221138045 creator A5081199627 @default.
- W4221138045 creator A5085405031 @default.
- W4221138045 creator A5086963427 @default.
- W4221138045 creator A5090818815 @default.
- W4221138045 date "2022-03-28" @default.
- W4221138045 modified "2023-10-15" @default.
- W4221138045 title "Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans" @default.
- W4221138045 cites W1495576644 @default.
- W4221138045 cites W1589766395 @default.
- W4221138045 cites W1942129679 @default.
- W4221138045 cites W1997579117 @default.
- W4221138045 cites W2010628484 @default.
- W4221138045 cites W2017081079 @default.
- W4221138045 cites W2018687481 @default.
- W4221138045 cites W2027684043 @default.
- W4221138045 cites W2031944234 @default.
- W4221138045 cites W2066586758 @default.
- W4221138045 cites W2075901113 @default.
- W4221138045 cites W2082703193 @default.
- W4221138045 cites W2088540000 @default.
- W4221138045 cites W2090355944 @default.
- W4221138045 cites W2099797203 @default.
- W4221138045 cites W2100327161 @default.
- W4221138045 cites W2100612316 @default.
- W4221138045 cites W2104347254 @default.
- W4221138045 cites W2105426251 @default.
- W4221138045 cites W2135514753 @default.
- W4221138045 cites W2151016309 @default.
- W4221138045 cites W2171747665 @default.
- W4221138045 cites W2173167364 @default.
- W4221138045 cites W2198093519 @default.
- W4221138045 cites W2213828346 @default.
- W4221138045 cites W2328433031 @default.
- W4221138045 cites W2341141208 @default.
- W4221138045 cites W2345520280 @default.
- W4221138045 cites W2491081100 @default.
- W4221138045 cites W2532213304 @default.
- W4221138045 cites W2560367415 @default.
- W4221138045 cites W2572174216 @default.
- W4221138045 cites W2582686270 @default.
- W4221138045 cites W2586097538 @default.
- W4221138045 cites W2607954371 @default.
- W4221138045 cites W2614968685 @default.
- W4221138045 cites W2734944743 @default.
- W4221138045 cites W2767275374 @default.
- W4221138045 cites W2770828094 @default.
- W4221138045 cites W2773830451 @default.
- W4221138045 cites W2783667606 @default.
- W4221138045 cites W2896311970 @default.
- W4221138045 cites W2897257669 @default.
- W4221138045 cites W2897704361 @default.
- W4221138045 cites W2898415660 @default.
- W4221138045 cites W2944904230 @default.
- W4221138045 cites W2946828413 @default.
- W4221138045 cites W2955930663 @default.
- W4221138045 cites W2970472714 @default.
- W4221138045 cites W2976334328 @default.
- W4221138045 cites W2977255036 @default.
- W4221138045 cites W2982425966 @default.
- W4221138045 cites W2990041408 @default.
- W4221138045 cites W2990332431 @default.
- W4221138045 cites W3001408868 @default.